| A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors (NCT07730190) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2026-08-01 |
| Treatment of Recurrent/Metastatic Head and Neck Cancer (NCT07601204) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2026-06-01 |
| Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (NCT07385703) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2026-04-15 |
| Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis (NCT07398859) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2026-03-19 |
| Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients (NCT07266116) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-12-26 |
| Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers (NCT07260708) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-12-16 |
| Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (NCT07165951) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-12-02 |
| Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma (NCT07187960) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-11-01 |
| Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps (NCT07107256) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-09-25 |
| Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies (NCT07110194) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-09-01 |
| TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection (NCT06829784) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-03-21 |
| Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma (NCT06854445) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-03-12 |
| Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis (NCT06760182) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2025-03-10 |
| A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06707883) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2024-12-31 |
| To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis (NCT06552520) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2024-10-08 |